Skip to content
thestock.space

On 6 Nov 2026, Metropolis Healthcare was priced at ₹568.75, or 52.8× trailing earnings, against an industry P/E of 52.8×. It earns ROCE of 16% and ROE of 15%, and sales and net profit grew 13% and 10.0% a year over 3 years. Its dividend yield is 0.3%, and debt is 0.16× equity. It is a small-cap company with a market cap of ₹11,803 Cr, ranked 5th of 18 Diagnostics & Research companies by market cap; the shares rose 12% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹570.00
Day high
₹573.60
Day low
₹565.10
Prev. close
₹571.00
Volume
2 L

Health check

1 good · 4 fair · 1 to check
  • ReturnsIn line

    +12.5% over a year, better than 4 of 7 peers.

  • Price tagIn line

    P/E 52.8 vs industry 52.8.

  • GrowthSlow

    Sales +12.7%, profit +10.0% a year over 3 years.

  • ProfitabilityAverage

    ROCE 15.7% vs peer median 19.1%.

  • Balance sheetFair

    Debt 0.16× equity, interest covered 11.6×, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Small cap

₹11,803 Cr, #5 of 18 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹1,783 Cr · profit ₹224 Cr
Market cap
₹11,803 Cr
Small cap
P/E
52.8
Industry 52.8
Price to book
7.17
Peers 11.99
Dividend yield
0.35%
ROE
14.6%
Peers 17.7%
ROCE
15.7%
Peers 19.1%
Debt to equity
0.16
Debt ₹268 Cr
EPS (TTM)
₹10.77
Face value ₹2
OPM (TTM)
25.2%
Net margin 12.6%
Sales growth
+15.8%
Latest quarter vs a year ago
Profit growth
+43.0%
Latest quarter vs a year ago
Price to sales
6.62
EV/EBITDA 33.5

Strengths and risks

Strengths

  • Quarterly profit up 43.0% on a year ago.
  • Quarterly sales up 15.8% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Metropolis Healthcare

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including…

Headquarters
Mumbai
Employees
4,484
Sector
Healthcare
ISIN
INE112L01020
Website
metropolisindia.com

Price range

52 weeks

₹412.25₹609.05

Today

₹565.10₹573.60
Avg volume (3M)
2.5 L
1-year return
plus 12.5%
From 52-week high
minus 6.6%

Analyst consensus

19 analysts
BuyMean target ₹674.58 plus 18.6%

Target range, with today’s price

Low ₹550.00High ₹886.00

Next results expected around 3 Feb 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Diagnostics & Research

Compare with peersScreen the whole industry
Company
SAILIFESai Life Sciences1,785.10plus 11.95%37,929101.515.2218.1%15.1%28.7%21.3%226.8%0.00%plus 72.7%
LALPATHLABDr. Lal Path Labs1,970.00plus 0.16%32,94156.511.9925.7%22.6%30.2%11.1%28.3%1.02%plus 24.7%
SYNGENESyngene International417.30plus 0.77%16,77290.33.468.3%3.9%25.7%5.4%−12.0%0.30%minus 36.0%
VIJAYAVijaya Diagnostic Centre1,468.60plus 2.15%15,12674.414.2919.1%21.2%43.1%21.0%26.9%0.14%plus 40.2%
METROPOLISMetropolis Healthcare568.75minus 0.39%11,80352.87.1715.7%14.6%21.7%12.7%10.0%0.35%plus 12.5%
THYROCAREThyrocare Technologies493.10plus 0.68%7,84855.014.7533.8%26.4%32.2%16.7%36.2%1.89%plus 8.3%
VIMTALABSVimta Labs496.45minus 2.14%2,21927.94.5221.0%17.7%34.7%8.9%17.2%0.40%minus 23.3%
SURAKSHASuraksha Diagnostic333.55plus 0.68%1,73748.57.0714.7%14.1%21.8%17.7%70.3%0.15%plus 2.2%
Median of 7 peers–0.68%15,12656.511.9919.1%17.7%30.2%16.7%28.3%0.30%8.3%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
429406425450497
321311317339363
10894.8108111134
25.2%23.4%25.4%24.7%27.0%
−4.898.25.18.5
–5.77.96.27
32.431.938.632.433
–−9.10.1––
7157.269.877.7102
25.5%26.4%27.0%26.8%26.3%
52.741.450.956.775.3
2.531.992.462.733.60

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+12.7%
Profit CAGR 3Y
+10.0%
EPS CAGR 3Y
+9.7%
ROE
14.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,1481,2081,3311,646
–+5.2%+10.2%+23.6%
8509101,0171,214
298298315432
26.0%24.7%23.6%26.2%
5−7.3−2.911.9
26.822.518.624.5
89.294.5109134
0.51.16.5−26.4
188175191259
23.5%26.5%23.8%26.2%
143128145190
–minus 10.5%+13.4%+31.1%
6.956.227.049.19

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.210.210.441.5
9781,0861,3211,472
266197204232
247262332393
1,5021,5551,8672,138
311336361415
0.30.315
1.95.972.2
94.1124118203
1,0951,0881,3801,513
1,5021,5551,8672,138

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
247264263351
46.8−89.4−201−223
−292−181−86.6−115
1.6−6.5−24.912.3
−52.6−63.8−68.6−51.2
194200194300
−41−20.5–−20.7

Shareholding pattern

Source: NSE filings
47.8%
promoters
  • Promoters47.82%
  • Public52.18%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202647.82%52.18%minus 1.04
30 Jun 202648.86%51.14%minus 0.01
31 Mar 202648.87%51.13%0.00
23 Mar 202648.87%51.13%minus 0.01
31 Dec 202548.88%51.12%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you